Get the Stockscreener App
4.00
3.90%
0.15
After Hours:
4.02
0.02
+0.50%
Ataibeckley Inc stock is traded at $4.00, with a volume of 3.31M.
It is up +3.90% in the last 24 hours and up +8.40% over the past month.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
See More
Previous Close:
$3.85
Open:
$3.87
24h Volume:
3.31M
Relative Volume:
0.75
Market Cap:
$1.46B
Revenue:
$4.09M
Net Income/Loss:
$-660.15M
P/E Ratio:
-1.7351
EPS:
-2.3053
Net Cash Flow:
$-117.10M
1W Performance:
+6.38%
1M Performance:
+8.40%
6M Performance:
-32.89%
1Y Performance:
+187.77%
1-Day Range:
$3.86
$4.00
1-Week Range:
$3.565
$4.00
52-Week Range:
$1.29
$6.75
Ataibeckley Inc Stock (ATAI) Company Profile
Name
Ataibeckley Inc
Sector
Industry
Phone
1 929 207 2670
Address
C/O ATAI LIFE SCIENCES US, INC., NEW YORK
Compare ATAI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATAI
Ataibeckley Inc
|
4.00 | 1.40B | 4.09M | -660.15M | -117.10M | -2.3053 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Deutsche Bank | Buy |
| Jan-20-26 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Needham | Buy |
| Jul-29-25 | Initiated | Oppenheimer | Outperform |
| Nov-18-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-03-24 | Upgrade | Maxim Group | Hold → Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
| Nov-11-21 | Initiated | ROTH Capital | Buy |
| Oct-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-01-21 | Initiated | Jefferies | Buy |
| Jul-13-21 | Initiated | Berenberg | Buy |
| Jul-13-21 | Initiated | Canaccord Genuity | Buy |
| Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-13-21 | Initiated | Credit Suisse | Outperform |
| Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
Ataibeckley Inc Stock (ATAI) Latest News
AtaiBeckley (ATAI) Reports Phase 2a Data in CNS Drugs - MSN
HC Wainwright bullish on AtaiBeckley (ATAI) - MSN
Johnson & Johnson’s Spravato sales growth signals upside for psychedelics peers - Proactive financial news
AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences - National Today
AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences - GlobeNewswire Inc.
Positive Phase 2a TRD Data For BPL-003 Might Change The Case For Investing In AtaiBeckley (ATAI) - simplywall.st
5 Stocks Under $5 That Will Explode - insidermonkey.com
AtaiBeckley (HAM:9VC) Cyclically Adjusted Price-to-FCF : (As of Apr. 11, 2026) - GuruFocus
Psychedelic: AtaiBeckley reports publication of BPL-003 study results - TipRanks
Analysts Are Bullish on These Healthcare Stocks: Atai Beckley N.V. (ATAI), MapLight Therapeutics, Inc. (MPLT) - The Globe and Mail
AtaiBeckley Depression Drug Delivers Rapid Day-2 Antidepressant Response - Sahm
Ataibeckley depression drug delivers rapid day-2 antidepressant response - MSN
AtaiBeckley: 'Buy' On New Key Developments For BPL-003 For TRD (NASDAQ:ATAI) - Seeking Alpha
Small cap wrap: AtaiBeckley, EDM Resources, Genflow Biosciences… - Proactive financial news
AtaiBeckley reports rapid response in Phase 2a trial of depression drug BPL-003 - Yahoo! Finance Canada
AtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs - Investing News Network
AtaiBeckley's BPL-003 May Lay the Foundation for a Scalable Mental Health System—The Outcome of 2026 Phase 3 Studies Will Determine Its Future - Bitget
AtaiBeckley reports positive phase 2a data for depression drug - Investing.com
AtaiBeckley Announces Positive Phase 2a Results for BPL-003 in Treatment-Resistant Depression with FDA Breakthrough Therapy Designation - Quiver Quantitative
AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs - The Manila Times
AtaiBeckley reports positive phase 2a data for depression drug By Investing.com - Investing.com UK
AtaiBeckley (ATAI) Valuation Check After Earnings Beat And Mental Health Pipeline Progress - simplywall.st
Deutsche Bank confident of AtaiBeckley Inc. (ATAI) growth prospects on psychedelic medicines - MSN
Deutsche Bank Confident of AtaiBeckley Inc. (ATAI) Growth Prospects on Psychedelic Medicines - Insider Monkey
AtaiBeckley Inc. (ATAI) latest stock news and headlines - Yahoo Finance Singapore
Why AtaiBeckley (ATAI) Is Up 13.1% After Deutsche Bank Highlights Its Post-Merger Pipeline Potential - simplywall.st
AtaiBeckley Inc. (B72.DE) - Yahoo! Finance Canada
ATAI Stock Price, Quote & Chart | ATAIBECKLEY INC (NASDAQ:ATAI) - ChartMill
Deutsche Bank initiates bullish coverage of psychedelics company AtaiBeckley - Mugglehead Investment Magazine
AtaiBeckley Is Said to Explore Options for Main Psychedelic Drug - MSN
AtaiBeckley Inc (ATAI) Stock Price Quote Today & Current Price Chart - Capital.com
Over-the-top psychedelic promos could undermine the field’s drug development efforts - statnews.com
AtaiBeckley Inc (ATAI) Stock Price Quote Today & Current Price Chart | Capital.com Australia - Capital.com
Is Ataibeckley Inc (ATAI) looking to sell its flagship psychedelic drug candidate BPL-003? - MSN
ATAI Technical Analysis | Trend, Signals & Chart Patterns | ATAIBECKLEY INC (NASDAQ:ATAI) - ChartMill
Is It Time To Reassess AtaiBeckley (ATAI) After Its Recent Share Price Slide? - simplywall.st
AtaiBeckley Weighs BPL-003 Deal After Strong Phase 2a And FDA Support - Yahoo Finance
Is Psychedelic Nasal Spray Data And Index Inclusion Altering The Investment Case For AtaiBeckley (ATAI)? - simplywall.st
Deutsche Bank initiates coverage of AtaiBeckley (ATAI) with buy recommendation - MSN
AtaiBeckley Inc. Trade Ideas — TRADEGATE:B72 - TradingView
AtaiBeckley awarded ‘Buy’ rating in initial coverage from Deutsche Bank analysts - Yahoo! Finance Canada
AtaiBeckley initiated with a Buy at Deutsche Bank - TipRanks
Deutsche Bank Initiates AtaiBeckley at Buy With $12 Price Target - MarketScreener
Deutsche Bank initiates Atai Life Sciences stock at buy on psychedelic therapy potential - Investing.com India
Deutsche Bank Initiates AtaiBeckley(ATAI.US) With Buy Rating, Announces Target Price $12 - Moomoo
Deutsche Bank initiates Atai Life Sciences stock at buy on psychedelic therapy potential By Investing.com - Investing.com South Africa
AtaiBeckley sees promising mid-stage results for psychedelic antidepressant - MSN
Ataibeckley Inc Stock (ATAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):